<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03189667</url>
  </required_header>
  <id_info>
    <org_study_id>RC16/035/R</org_study_id>
    <nct_id>NCT03189667</nct_id>
  </id_info>
  <brief_title>Drug Coated Balloons vs Plain Balloons for the Management of Dysfunctional Dialysis Fistula</brief_title>
  <official_title>Drug Coated Balloons vs Plain Balloons for the Management of Dysfunctional Dialysis Fistula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Abdullah International Medical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Abdullah International Medical Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the effectiveness of drug-coated balloons to plain balloon angioplasty in reducing&#xD;
      stenosis rates in dialysis arteriovenous fistulas (AVFs).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives of the Study:&#xD;
&#xD;
      Hypothesis: Drug-coated balloons improve functional and patency outcomes of&#xD;
      failing/dysfunctional hemodialysis fistulas compared to plain uncoated balloons&#xD;
&#xD;
      Aim of the Study:&#xD;
&#xD;
      Compare the effectiveness of drug-coated balloons to plain balloon angioplasty in reducing&#xD;
      stenosis rates in dialysis AVFs.&#xD;
&#xD;
      Specific Objectives:&#xD;
&#xD;
      Primary functional endpoint: Access circuit patency based on functional criteria at 12 month.&#xD;
&#xD;
      Primary safety endpoint: Peri procedural complication rate&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  Technical success (&lt;30% residual stenosis without postdilation)&#xD;
&#xD;
        -  Access circuit dysfunction free survival (Time to event) based on functional criteria&#xD;
&#xD;
        -  Target lesion restenosis free survival (Time to event) (in case of new lesion causes&#xD;
           circuit dysfunction)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow recruitment and recent concerns of safety of Paclitaxel coated balloons and associated&#xD;
    increased risk death&#xD;
  </why_stopped>
  <start_date type="Actual">October 15, 2017</start_date>
  <completion_date type="Actual">February 5, 2019</completion_date>
  <primary_completion_date type="Actual">February 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open label randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AVF circuit patency</measure>
    <time_frame>12 month</time_frame>
    <description>Dialysis adequacy to be assessed based on functional criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>intra procedural</time_frame>
    <description>&lt;30% residual stenosis without postdilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access circuit dysfunction free survival</measure>
    <time_frame>12 month</time_frame>
    <description>Time to event based on functional criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion restenosis free survival</measure>
    <time_frame>12 month</time_frame>
    <description>Time to event in case of new lesion causes circuit dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>12 month following the procedure</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by the Society of Interventional Radiology Clinical Practice Guidelines</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Dysfunctional Dialysis Arteriovenous Fistula</condition>
  <arm_group>
    <arm_group_label>Drug coated balloon angioplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vessel preparation with Pre dilatation&#xD;
Vessel treatment with Drug-coated balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plain balloon angioplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vessel preparation with Pre dilatation&#xD;
Vessel treatment with additional Plain balloon angioplasty:</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vessel preparation with angioplasty</intervention_name>
    <description>Vessel preparation with Pre dilatation:&#xD;
All lesions to be predilated with high pressure balloons until waist is obliterated.&#xD;
At least two minutes dilatation.&#xD;
Balloon sizing: not to exceed the average diameter of adjacent normal appearing non-aneurysmal segments by more than 25%.&#xD;
Multiple lesions:&#xD;
To be treated with single balloon if possible.&#xD;
To be treated with multiple inflation if cannot be covered with single balloon.</description>
    <arm_group_label>Drug coated balloon angioplasty</arm_group_label>
    <arm_group_label>Plain balloon angioplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Plain balloon angioplasty</intervention_name>
    <description>Plain balloon angioplasty&#xD;
Vessel treatment with additional Plain balloon angioplasty:&#xD;
Inflation to nominal pressure for at least 1 minute.&#xD;
Balloon size: similar to predilation balloon.</description>
    <arm_group_label>Plain balloon angioplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug coated balloon angioplasty</intervention_name>
    <description>Lutonix® Drug Coated Balloon: The balloon is coated with a specialized formulation that includes the drug, paclitaxel. The paclitaxel coating is evenly distributed across the working length of the balloon at a surface concentration of 2 μg/mm2. The key functional characteristic of the formulation is to allow for release of paclitaxel to the tissue of the vascular wall during inflation.&#xD;
Inflation to nominal pressure for at least 1 minute.&#xD;
Balloon size: similar to the predilation balloon.&#xD;
New drug coated balloon will be required for each lesion.</description>
    <arm_group_label>Drug coated balloon angioplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria&#xD;
&#xD;
               -  &gt;18 year old&#xD;
&#xD;
               -  Dysfunctional dialysis fistula&#xD;
&#xD;
          -  Radiocephalic&#xD;
&#xD;
          -  Brachiocephalic&#xD;
&#xD;
          -  Brachiobasilic&#xD;
&#xD;
        Clinical criteria for diagnosis of dysfunctional fistula:&#xD;
&#xD;
          -  Swelling of the fistula limb&#xD;
&#xD;
          -  Prolonged bleeding after withdrawing access needles&#xD;
&#xD;
          -  Abnormal pulsations or weak thrill.&#xD;
&#xD;
          -  Functional criteria for the diagnosis of dysfunctional criteria:&#xD;
&#xD;
          -  Arteriovenous fistula is unable to deliver dialysis blood flow (Qb) of equal to or&#xD;
             more than 300 ml/min and/or access recirculation of more than 10% on at least two&#xD;
             occasions,&#xD;
&#xD;
          -  A rising trend of venous pressure or excessive negative arterial pressure, and/or&#xD;
             unable to deliver a Kt/v of 1.2 or more.&#xD;
&#xD;
          -  Non-thrombosed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dysfunctional arteriovenous (AV) grafts&#xD;
&#xD;
          -  Thrombosed fistulas&#xD;
&#xD;
          -  Intra-stent stenosis&#xD;
&#xD;
          -  Stenoses not responding to balloon angioplasty and requiring stenting.&#xD;
&#xD;
          -  Stenosis less than 50%&#xD;
&#xD;
          -  Surgical intervention that excludes the treatment segment from the access circuit&#xD;
&#xD;
          -  Systemic or local (to the fistula) infection treated for less than 10 days prior to&#xD;
             the study procedure&#xD;
&#xD;
          -  Location of isolated stenosis central to the thoracic inlet.&#xD;
&#xD;
          -  Women who are breastfeeding, pregnant or are intending to become pregnant&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to contrast medium which cannot be&#xD;
             adequately premeditated.&#xD;
&#xD;
          -  Sensitivities to heparin, aspirin, other anticoagulant/antiplatelet therapies, and/or&#xD;
             paclitaxel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad Arabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Abdulaziz Medical City</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King ABdulaziz Medical City</name>
      <address>
        <city>Riyadh</city>
        <zip>11426</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>April 28, 2019</last_update_submitted>
  <last_update_submitted_qc>April 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>April 1, 2021</submitted>
    <returned>April 27, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

